Teva confirms launch of generic Viagra in Europe

Generic Viagra has been launched after expiry of patents in the UK, Germany, Italy, Holland, Switzerland, Ireland, Austria, Belgium and Denmark.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of a generic version of Viagra (Sildenafil) in Europe, confirming last week's report by "Globes.

"

Teva has launched the drug immediately upon the expiry of brand Viagra's patents in the UK, Germany, Italy, the Netherlands, Switzerland, Ireland, Austria, Belgium and Denmark. It has already launched the product in Spain, Canada, and certain other countries.

Teva is delivering generic Viagra for the treatment of impotence and erectile dysfunction through its wholesaler and pharmacy channels. In line with European legislation, it will not offer the product directly to consumers.

Teva Europe Generics president and CEO Dipankar Bhattacharjee said, “Teva has a proud track record of bringing high-quality generics to the market on day one of patent expiry, and we have been able to launch sildenafil immediately on patent expiry in all the major markets of Europe. The launch today of Sildenafil will bring choice to the pharmacy to help them serve the patient, and to help ensure that high-quality healthcare in Europe is affordable."

Published by Globes [online], Israel business news - www.globes-online.com - on June 24, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס